News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,725 Results
Type
Article (13950)
Company Profile (304)
Press Release (247471)
Section
Business (79356)
Career Advice (151)
Deals (13190)
Drug Delivery (34)
Drug Development (50332)
Employer Resources (31)
FDA (5682)
Job Trends (5116)
News (144138)
Policy (10018)
Tag
Academia (901)
Alliances (21525)
Alzheimer's disease (758)
Approvals (5663)
Artificial intelligence (68)
Bankruptcy (97)
Best Places to Work (4522)
Biotechnology (249)
Breast cancer (109)
Cancer (889)
Cardiovascular disease (71)
Career advice (132)
CAR-T (73)
Cell therapy (217)
Clinical research (40139)
Collaboration (308)
Compensation (128)
COVID-19 (1006)
C-suite (78)
Cystic fibrosis (67)
Data (984)
Diabetes (86)
Diagnostics (1207)
Drug discovery (57)
Earnings (29005)
Events (47193)
Executive appointments (247)
FDA (6050)
Funding (306)
Gene editing (63)
Gene therapy (163)
GLP-1 (311)
Government (1065)
Healthcare (6543)
Infectious disease (1043)
Inflammatory bowel disease (98)
IPO (7197)
Job creations (859)
Job search strategy (127)
Layoffs (188)
Legal (1375)
Lung cancer (130)
Lymphoma (62)
Manufacturing (86)
Medical device (2558)
Medtech (2559)
Mergers & acquisitions (6128)
Metabolic disorders (259)
Neuroscience (1001)
NextGen Class of 2024 (2004)
Non-profit (847)
Northern California (1091)
Obesity (140)
Opinion (91)
Parkinson's disease (76)
Patents (61)
People (25104)
Phase I (14151)
Phase II (18665)
Phase III (11818)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (202)
Real estate (1409)
Regulatory (8284)
Research institute (931)
Southern California (976)
Startups (1965)
United States (8660)
Vaccines (164)
Weight loss (84)
Date
Today (9)
Last 7 days (367)
Last 30 days (1382)
Last 365 days (20537)
2024 (20449)
2023 (22413)
2022 (26823)
2021 (27805)
2020 (23357)
2019 (16225)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14350)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7615)
2010 (7428)
Location
Africa (146)
Asia (16924)
Australia (2856)
California (2474)
Canada (809)
China (204)
Colorado (91)
Connecticut (103)
Europe (36446)
Florida (272)
Georgia (71)
Illinois (153)
Indiana (61)
Kansas (55)
Maryland (330)
Massachusetts (1956)
Minnesota (102)
New Jersey (631)
New York (683)
North Carolina (419)
Northern California (1091)
Ohio (82)
Pennsylvania (474)
South America (207)
Southern California (976)
Texas (278)
Washington State (247)
261,725 Results for "dermata therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 14, 2024
·
7 min read
Press Releases
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
December 17, 2024
·
6 min read
Business
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq;DRMAW) (“Dermata,” or the “Company”), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent corporate progress and reported financial results for the first quarter ended March 31, 2024.
May 15, 2024
·
7 min read
News
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
October 8, 2024
·
3 min read
Business
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
Dermata Therapeutics, Inc. (Nasdaq: DRMA)(Nasdaq:DRMAW) (“Dermata,” or the “Company”), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent corporate progress and reported financial results for the full year ended December 31, 2023.
March 21, 2024
·
7 min read
Biotech Beach
Dermata to Present at the Emerging Growth Conference on April 3, 2024
Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) (“Dermata” or the “Company”), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the Emerging Growth Conference on April 3, 2024.
March 27, 2024
·
4 min read
Press Releases
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
December 3, 2024
·
6 min read
Deals
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Dermata Therapeutics, Inc. today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 516,336 shares of the Company’s common stock, having exercise prices of $9.7665 and $32.
May 17, 2024
·
5 min read
Press Releases
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
September 17, 2024
·
5 min read
Biotech Beach
Dermata to Present at the Emerging Growth Conference on February 7, 2024
Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) (“Dermata” or the “Company”), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the Emerging Growth Conference on February 7, 2024.
February 1, 2024
·
4 min read
1 of 26,173
Next
